ITGB2 and infection: A similar type of argument may well be advanced and applicable to SARS-CoV-2 entering their primary infection-resistant ACE2-negative target cells, using manipulated Jurkat cells in vitro, reportedly via LFA-1, similar to HIV-1 vis-à-vis LFA-1 (Hioe et al., 2001; Shen et al., 2022).